ProPhase Labs

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ProPhase Labs achieves record revenues, Nebula Genomics poised for growth

ProPhase Labs delivered strong financial performance in 2022, showcasing a successful transformation and diversification strategy.
The company's subsidiaries, particularly Nebula Genomics and BE-Smart, offer significant growth potential and differentiation in their respective markets.
While challenges like declining COVID testing trends and financial impacts exist, strategic opportunities and efficient management position ProPhase Labs for continued success.

ProPhase Labs prioritizes value-building over earnings, eyes global growth

ProPhase Labs is strategically focusing on long-term value creation through its diverse business segments.
While facing challenges in COVID testing and profitability, the company is optimistic about revenue growth from key assets.
Opportunities in precision medicine, cancer compounds, and global expansion present avenues for future growth.

ProPhase Labs shifts focus to genetic testing, eyes global expansion

ProPhase Labs is strategically pivoting towards genetic testing with Nebula Genomics, focusing on advanced laboratory capabilities and potential revenue generation. Despite revenue declines in Q2, the company remains optimistic about future growth prospects and is actively exploring financing options for expansion.

ProPhase Labs anticipates substantial growth with innovative healthcare solutions

ProPhase Labs is strategically positioned for growth with strong demand for its subsidiaries and innovative healthcare solutions in development.
While facing challenges in market conditions and revenue guidance, the company's focus on expansion and efficiency drives optimism for future performance.
Opportunities lie in revenue and profitability increases, potential IPOs, and advancements in esophageal cancer testing techniques and therapeutics.
Investors are encouraged to consider the long-term potential of ProPhase Labs as it navigates challenges and capitalizes on growth prospects.

ProPhase Labs excels in Q4, eyes revenue growth and strategic partnerships

ProPhase Labs showcased strong historical performance, profitable business segments, and strategic growth initiatives. The company is poised for substantial revenue growth through key contracts, innovative product offerings, and expansion into new markets. Challenges in short-term profitability and regulatory restrictions are being addressed while focusing on long-term value creation and growth potential.

ProPhase Labs (PRPH) reports strong performance and explores strategic opportunities

ProPhase Labs (PRPH) showcased strong historical performance, highlighted key initiatives like Pharmaloz and Nebula Genomics, and emphasized the potential for liquidity events. Challenges include revenue growth uncertainty and transparency concerns over share count increase.

ProPhase Labs strategizes for growth amidst seasonality and liquidity concerns

ProPhase Labs is navigating mixed performance with a focus on strategic initiatives, liquidity management, and maximizing shareholder value.
The company's strengths lie in its leadership team, growth potential in precision medicine, and plans for mitigating seasonality in revenue streams.
Challenges include seasonality impact, liquidity concerns, and the need for successful execution of strategic alternatives for Pharmaloz.
Opportunities exist in partnerships for Pharmaloz, growth potential in precision medicine, and anticipated revenue growth in the upcoming quarters.

ProPhase Labs excels in Q3 with innovative healthcare solutions

ProPhase Labs' Q3 earnings call highlighted strong performance, innovative healthcare solutions, and strategic growth initiatives.
The company's focus on fiscal conservatism, cost reduction, and potential partnerships positions it for future success and market expansion.
Challenges in cost management and market dynamics are balanced by opportunities in partnerships, product expansion, and revenue growth strategies.
Overall, ProPhase Labs remains optimistic about its future prospects, emphasizing prudent financial management and growth through strategic collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company Also Announces First Licensing Agreement for PBIO with Global BioLife, Inc. for broad based Anti-Viral Fighting Compounds Equivir and Equivir G

ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology

ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ProPhase Labs, Inc. (PRPH) Surges 7.6%: Is This an Indication of Further Gains?

Here is how ProPhase Labs, Inc. (PRPH) and RVL Pharmaceuticals PLC (RVLP) have performed compared to their sector so far this year.

Is ProPhase Labs (PRPH) Outperforming Other Medical Stocks This Year?

Expanding in-house clinical testing capabilities

ProPhase Labs Announces Significant Laboratory Expansion

Has ProPhase Labs (PRPH) Outpaced Other Medical Stocks This Year?

ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ProPhase Labs, Inc. (PRPH) Moves to Strong Buy: Rationale Behind the Upgrade

ProPhase Labs to Present at the H.C. Wainwright 2022 Global Investment Conference

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2022 Earnings Conference Call May 13, 2022 11:00 AM ET Company Participants Ted Karkus – Chairman & Chief Executive Officer Conference Call Participants Yi Chen – H.C. Wainwright & Co. Patrick Patterson – Home Robert Titus – MRT Industries Dennis Waldman – Barrett Productions Kyle Krueger – Apollo Capital Fred MacDonald – Private Investor Operator Good day and welcome to the ProPhase Labs First Quarter 2022.

ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q1 2022 Results - Earnings Call Transcript

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 74.36% and 95.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Tops Q1 Earnings and Revenue Estimates

Record Net Revenues of $47.5 Million, Up 211% Year-over-Year

ProPhase Labs Announces Record First Quarter 2022 Financial Results

Garden City, NY, May 11, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present at the Spring Into Action – Best Ideas Virtual Investor conference, which is being held virtually on May 17th-20th, 2022.

ProPhase Labs to Present at the Spring Into Action – Best Ideas Virtual Investor Conference

Garden City, NY, May 10, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified diagnostics and genomics company, announced today that Bill White has been appointed Chief Financial Officer (CFO) of ProPhase Labs, effective May 23, 2022.

ProPhase Labs Announces Appointment of Bill White as Chief Financial Officer

GARDEN CITY, NY, May 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, will hold a conference call on Friday, May 13, 2022 at 11:00 a.m. ET to discuss its results for the first quarter ended March 31, 2022. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022 at 11:00 a.m. Eastern Time

Garden City, NY, April 27, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present a corporate overview at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022 at 1:30 PM EST.

ProPhase Labs to Present at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022

All You Need to Know About ProPhase Labs, Inc. (PRPH) Rating Upgrade to Strong Buy

Hudson Technologies

ProPhase Labs (PRPH), Hudson Technologies (HDSN) and YPF Sociedad Anonima (YPF) have been selected as the breakout stocks for today.

3 Top Breakout Stocks to Buy for Remarkable Returns

ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

ProPhase Labs, Inc. (PRPH) Soars 11.2%: Is Further Upside Left in the Stock?

ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q4 2021 Results - Earnings Call Transcript

Record Financial Results also expected for Q1 2022

ProPhase Labs Announces Record Financial Results for the Fourth Quarter and Full Year Ended December 31, 2021

GARDEN CITY, NY, March 24, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified company offering a range of services including diagnostic testing, genomics testing and contract manufacturing, will hold a conference call on Wednesday, March 30, 2022 at 11:00 a.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2021. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 30, 2022 at 11:00 a.m. Eastern Time

Anticipates Record Q4 2021 and Q1 2022 Revenues and Profits

ProPhase Labs Announces Special Cash Dividend

GARDEN CITY, NY, Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the MicroCap Rodeo Winter Wonderland Best Ideas Conference, which is being held virtually from February 8 – 11, 2022.

ProPhase Labs to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Conference

Q1 2022 Testing Volumes will Significantly Exceed Previous Record Results from Q1 2021

ProPhase Labs Announces Record COVID-19 Testing in Q4 2021

Precision Medicine division adds Industry Veteran Sam A. Beeler as Chief Strategy Officer; Diagnostics Division Promotes Alice Lioi and Jason Karkus to EVP and Co-Chief Operating Officers and Sergio Miralles to EVP/ Chief Information Officer

ProPhase Labs Continues to Build Strong Leadership with Key Promotions and Additions to Management Team

GARDEN CITY, NY, Nov. 23, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, today announced that it has granted an inducement award to a new employee.

News for ProPhase Labs Stock (PRPH)